Serum matrix metalloproteinase-9 level in systemic lupus erythematosus with peripheral neuropathy
| Autor: | Mohamed Hassan Imam, Abeer S. El-Hadidi, Niveen Abdallah Ibrahim, Hamdy Khamis Koriem, Marwa Hassan |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
medicine.medical_specialty
peripheral neuropathy Anti-nuclear antibody Lupus nephritis 030209 endocrinology & metabolism Diseases of the musculoskeletal system Gastroenterology 03 medical and health sciences 0302 clinical medicine systemic lupus erythematosus immune system diseases matrix metalloproteinase-9 Internal medicine medicine skin and connective tissue diseases 030203 arthritis & rheumatology Systemic lupus erythematosus biology business.industry Matrix metalloproteinase 9 Odds ratio medicine.disease Peripheral neuropathy RC925-935 biology.protein Antibody medicine.symptom business Malar rash |
| Zdroj: | Egyptian Rheumatology and Rehabilitation, Vol 46, Iss 4, Pp 211-220 (2019) |
| ISSN: | 2090-3235 1110-161X |
| DOI: | 10.4103/err.err_45_19 |
| Popis: | Objective To evaluate whether serum matrix metalloproteinase-9 (MMP-9) is associated with peripheral neuropathy (PN) in patients with systemic lupus erythematosus (SLE) and to determine the relationship between MMP-9 serum level and SLE disease activity, lupus manifestations, and laboratory markers. Patients and methods A total of 30 patients with SLE with PN, 30 patients with SLE without PN, and 20 healthy controls were included in this study. SLE clinical manifestations, Systemic Lupus Activity Measure (SLAM) index, and laboratory markers were evaluated. All the data were compared and correlated with serum MMP-9 level. Results MMP-9 showed a significant increase in frequency in SLE with PN group compared with SLE without PN group (P1=0.037), SLE with PN group compared with control group (P2 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink